Research ArticleOpen AccessGoogle Scholar indexed
Financing Innovative Medicines in Mainland China: The Role of Commercial Health Insurance
Bristol-Myers Squibb Company, Wallingford, USA
Peking University, Beijing, China
Janssen Pharmaceutical Companies of Johnson & Johnson, Singapore City, Singapore
- 1 Bristol-Myers Squibb Company, Wallingford, USA
- 2 Peking University, Beijing, China
- 3 Janssen Pharmaceutical Companies of Johnson & Johnson, Singapore City, Singapore
Copy link · social · email
Abstract
The National Reimbursement Drug List (NRDL) is a key component of the current government-led insurance policy to provide access to basic medicines in mainland China; yet NRDL coverage is limited due to public budgetary constraints and new, innovative medicines are often excluded. This paper explores the potential role of commercial health insurance as an optional approach to financing medicines excluded by the NRDL. The current status of commercial health insurance (CHI) in Mainland China is reviewed and we discuss proposed changes that may be needed to develop an effective and sustainable commercial insurance program to provide the Chinese population with better access to innovative medicines not covered by NRDL.
KeywordsMainland ChinaNRDLInnovative MedicinesCommercial Health Insurance
- Bhattacharjye, A. S., & Sapra, P. K. (2008). Health insurance in China and India: Segmented roles for public and private financing. Health Affairs, 27, 1005-1015. doi:10.1377/hlthaff.27.4.1005
- Chen, T., & Ye, X. (2007). Private health insurance and health actuary in mainland China. Proceedings of the 14th East Asian Actuarial Conference, Tokyo.
- China annual incomes (2013). http://money.cnn.com/2012/06/26/news/economy/china-middle-class/index.htm
- China government announcement (2012). http://www.google.com/search?q=ziyuanzhongxin+shujuziliao+book 335927+site:www.chira.org.cn
- China healthcare reform (2012). http://www.chira.org.cn/xinwenzhongxin/jiaodianxinwen/new337797.html
- China Insurance Regulatory Commission (2013). http://www.circ.gov.cn/web/site0/tab61/
- China Insurance Regulatory Commission (2010). http://www.circ.gov.cn/web/site0/tab211/i47326.htm
- China Insurance Regulatory Commission (2013). http://www.circ.gov.cn/web/site0/tab454/i191553.htm
- Drechsler, D., & Jutting, J. (2007). Different countries, different needs: The role of private health insurance in developing countries. Journal of Health Politics, Policy and Law, 32, 497-534. doi:10.1215/03616878-2007-012
- Gordon, R., Xu, T., & Xie, L. (2012). Brazil’s health insurance. http://www.google.com/search?safe=active&rlz=1T4MXGB_enUS546&q=Ronald+Gordon+and+Tian+Xu&oq=Ronald+Gordon+and+Tian+Xu& gs_l=serp.12..0i22i30.24027.62191.0.63861.56.40.0.0.0.0.3339.10282.0j1j4j2j6-1j0j1j2.11.0....0...1c.1.22.serp..46.10.10048.q8uuFXd4Z8s
- Hougaard, J. L., ?sterdal, L. P., & Yu, Y. (2008). The Chinese health care system: Structure, problems and challenges. No. 08-01. Discussion papers department of Economics University of Copenhagen, Copenhagen.
- Le Deu, F., Parekh, R., Zhang, F. N., & Zhou, G. (2012). Healthcare in China: “Entering uncharted waters”. New York: McKinsey & Company.
- MOH China statistics (2012). http://www.moh.gov.cn/publicfiles///business/cmsresources/mohwsbwstjxxzx/cmsrsdocument/doc15055.pdf
- National development and reform commission, China. (2013). http://shs.ndrc.gov.cn/ygid/ygwj/t200904080408_271138.htm
- NRDL in 2009 (Chinese medicines listing) (2013). http://www.china.com.cn/news/txt/2009-08/19/content_18359838.htm